Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
89bio logo — Developing and commercializing innovative therapies for the...

89bio

Developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic diseases

Founded 2018 United States San Francisco, United States 123 employees Post-IPO Equity Total: $773.20M Biopharma, Biotechnology +1

General Information

Company Name 89bio
Founded Year 2018
Location United States San Francisco, United States
Employees 123
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with 89bio. To contact 89bio, visit 89bio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does 89bio compare?

A PDF of 89bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting 89bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About 89bio

89bio

89bio is a clinical-stage biopharmaceutical company with a focus on developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic diseases. Their lead product candidate, BIO89-100, is an engineered glycoPEGylated analog of FGF21 designed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). The company's recent Phase 1b/2a data showed favorable safety and tolerability profiles and significant reductions in liver fat and key lipid markers in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. Founded in 2018 and headquartered in San Francisco with operations in Herzliya, Israel, 89bio upholds a strong set of values, including prioritizing patient needs, integrity, authenticity, teamwork, entrepreneurship, and scientific rationality.

The company's last investment of $150.00M in post-IPO equity occurred on 06 December 2023.

Business keywords: biopharmaceutical company, clinical-stage, FGF21 analog, NASH treatment, SHTG treatment, liver diseases, cardio-metabolic diseases, innovative therapies, Phase 2 trial, patient-centric, ethical standards, scientific advancement, San Francisco, Herzliya, Israel

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $150.00M -
06 Dec 2023
Post IPO Equity $275.00M -
24 Mar 2023
Post IPO Debt $25.00M 1
K2 HealthVentures
K2 HealthVentures
04 Jan 2023
Post IPO Equity $94.50M -
28 Jun 2022
Post IPO Secondary $83.80M -
14 Jul 2020
Post IPO Equity $84.90M -
11 Nov 2019
Series A $60.00M 4
Longitude Capital Pontifax RA Capital Management
Longitude Capital, Pontifax +2
25 Oct 2018

89bio Alternatives & Competitors

View All Alternatives
89bio vs
HighTide Therapeutics
HighTide Therapeutics China

East Meets West—The Quest for Cure

Series C
18 employees
Biotechnology, Health Care
Compare 89bio vs HighTide Therapeutics
89bio vs
Madrigal Pharmaceuticals
Madrigal Pharmaceuticals United States

Madrigal is focused on delivering novel therapeutics for MASH, a serious liver disease.

IPO
1129 employees
Biopharma, Biotechnology
Compare 89bio vs Madrigal Pharmaceuticals
89bio vs
Cirius Therapeutics
Cirius Therapeutics

Pioneering the future of liver and metabolic disease treatment with innovative insulin sensitizers.

Series A
Biopharma, Biotechnology
View all alternatives

FAQ About 89bio

Developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic diseases
89bio was founded in 2018.
89bio is headquartered in San Francisco, United States.
89bio operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on biopharmaceutical company, clinical-stage, FGF21 analog and NASH treatment.
89bio has approximately 123 employees.
89bio has completed 7 funding rounds, raising a total of $773.20M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to 89bio include HighTide Therapeutics, Madrigal Pharmaceuticals, Cirius Therapeutics, CymaBay Therapeutics, Theratechnologies Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
89bio and HighTide Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for 89bio, https://bouncewatch.com/company/89bio, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout